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BACKGROUND
The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as so-
tagliflozin in preventing cardiovascular events in patients with diabetes with chronic 
kidney disease with or without albuminuria have not been well studied.
METHODS
We conducted a multicenter, double-blind trial in which patients with type 2 dia-
betes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated 
glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface 
area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio 
to receive sotagliflozin or placebo. The primary end point was changed during the 
trial to the composite of the total number of deaths from cardiovascular causes, 
hospitalizations for heart failure, and urgent visits for heart failure. The trial 
ended early owing to loss of funding.
RESULTS
Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the 
sotagliflozin group and 5292 assigned to the placebo group, and followed for a 
median of 16 months. The rate of primary end-point events was 5.6 events per 100 
patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the 
placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; 
P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 
2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; 
P = 0.35). For the original coprimary end point of the first occurrence of death 
from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the 
hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point 
of the first occurrence of death from cardiovascular causes or hospitalization for 
heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital 
mycotic infections, volume depletion, and diabetic ketoacidosis were more common 
with sotagliflozin than with placebo.
CONCLUSIONS
In patients with diabetes and chronic kidney disease, with or without albuminuria, 
sotagliflozin resulted in a lower risk of the composite of deaths from cardiovas-
cular causes, hospitalizations for heart failure, and urgent visits for heart failure 
than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon 
Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.)
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Patients with diabetes mellitus are at high risk for both heart failure and ischemic events.1-7 Sodium–glucose cotrans-
porter 2 (SGLT2) inhibitors have been shown to 
be effective for the treatment of type 2 diabetes 
mellitus8-10 and to lower the risk of hospitaliza-
tion for heart failure among patients with or 
without previous heart failure.11-22 Their effect on 
different types of ischemic events has been more 
heterogeneous across drugs, trials, and popula-
tions. Coexisting chronic kidney disease in pa-
tients with diabetes mellitus further raises the 
risk of heart failure and ischemic events.23 Data 
from randomized trials support the use of 
SGLT2 inhibition in patients with chronic kidney 
disease with or without diabetes.12,19 These trials 
have required the presence of macroalbuminuria 
for inclusion, in addition to reduced estimated 
glomerular filtration rate (eGFR).
These considerations led to the design of the 
Effect of Sotagliflozin on Cardiovascular and Re-
nal Events in Patients with Type 2 Diabetes and 
Moderate Renal Impairment Who Are at Cardio-
vascular Risk (SCORED) trial. Sotagliflozin is an 
SGLT2 inhibitor that also inhibits gastrointesti-
nal SGLT1. Inhibition of SGLT2 increases urinary 
glucose excretion, whereas inhibition of SGLT1 
appears to delay glucose absorption and reduce 
postprandial glucose.24-29 We conducted this trial 
to determine whether sotagliflozin was noninfe-
rior to placebo with respect to ischemic events 
and whether it was superior with respect to heart 
failure events. On the basis of emerging data 
about SGLT2 inhibitors, we aimed to examine 
whether sotaglif lozin would reduce the total 
number of deaths from cardiovascular causes, 
hospitalizations for heart failure, and urgent 
visits for heart failure in patients with diabetes 
mellitus and chronic kidney disease, regardless 
of the degree of albuminuria.
Me thods
Trial Design
This was a phase 3, randomized, double-blind, 
placebo-controlled trial that compared sota-
glif lozin (200 mg once daily, with an increase to 
400 mg once daily if unacceptable side effects 
did not occur) with placebo in patients with type 
2 diabetes mellitus, chronic kidney disease, and 
additional cardiovascular risk; all the patients 
also received standard-of-care treatments. Ran-
domization was stratified according to criteria 
for heart failure (ejection fraction of ≤40% docu-
mented within the past year or hospitalization 
for heart failure during the previous 2 years) and 
geographic region (North America, Latin Amer-
ica, western Europe, eastern Europe, or rest of the 
world). The original plan was for approximately 
10,500 patients to undergo randomization, and 
this plan was accomplished. Final trial visits 
were initiated in March 2020 before the target 
number of events had occurred because of loss 
of funding from the sponsor.30 This led to a revi-
sion of end points, as indicated in the end-points 
section below and in the original and revised 
protocols, available with the full text of this ar-
ticle at NEJM.org. Details of the trial design are 
provided in Figure S1 in the Supplementary Ap-
pendix, available at NEJM.org. Patients were en-
rolled at 750 sites in 44 countries. The first pa-
tient underwent randomization on December 8, 
2017, and the last on January 20, 2020.
The original sponsor was Sanofi. Sponsorship 
was transferred to Lexicon Pharmaceuticals as 
of January 30, 2020. The executive and steering 
committees, consisting of academic physicians, 
and representatives from the sponsors developed 
the protocol and statistical analysis plan (avail-
able with the protocol at NEJM.org) and were 
responsible for the conduct and oversight of the 
trial, as well as the interpretation of data. The 
sponsors provided sotagliflozin and placebo and 
were responsible for the collection and handling 
of the data and funded the statistical analysis 
performed by an independent academic statisti-
cian (the second author). The protocol was ap-
proved by the relevant health authority, institu-
tional review board, or ethics committee at each 
trial site. The authors vouch for the complete-
ness and accuracy of the data, for the accurate 
and full reporting of adverse events, and for the 
fidelity of the trial to the protocol and statistical 
analysis plan. An independent data and safety 
monitoring board oversaw the trial. There were 
confidentiality agreements between the sponsors 
and the authors. The sponsor had the right to 
review and comment on the manuscript, with no 
obligation of the authors to incorporate any com-
ments, and the authors were not restricted from 
publishing the results of the trial.
Patients
Persons 18 years of age or older with type 2 dia-
betes mellitus with a glycated hemoglobin level of 
7% or higher, chronic kidney disease (eGFR, 25 to 
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60 ml per minute per 1.73 m2 of body-surface 
area), and additional cardiovascular risk factors 
were enrolled. The risk factors consisted of at 
least one major cardiovascular risk factor in those 
18 years of age or older or at least two minor 
cardiovascular risk factors in those 55 years of 
age or older. An exclusion criterion was any plan 
to start an SGLT2 inhibitor during the trial. In-
clusion criteria (including definitions of major 
and minor cardiovascular risk factors) and ex-
clusion criteria are listed in the Supplementary 
Appendix. Written informed consent was obtained 
from all the patients.
End Points
The original coprimary end points, assessed in 
time-to-event analyses, were the first occurrence 
of a major adverse cardiovascular event (MACE, 
defined as death from cardiovascular causes, non-
fatal myocardial infarction, or nonfatal stroke) and 
the first occurrence of death from cardiovascu-
lar causes or hospitalization for heart failure. 
Because of the early closing of the trial and the 
fewer than planned number of events, with the 
investigators and sponsor unaware of the trial-
group assignments and without end-point infor-
mation from an interim analysis, the primary end 
point was changed on August 21, 2020, to the total 
number of deaths from cardiovascular causes, 
hospitalizations for heart failure, and urgent 
visits for heart failure.
The original secondary end points were the 
first occurrence, in patients with a baseline eGFR 
of at least 30 ml per minute per 1.73 m2, of a 
sustained decrease of at least 50% in the eGFR 
from baseline for at least 30 days, long-term 
dialysis, renal transplantation, or a sustained 
eGFR of less than 15 ml per minute per 1.73 m2 
for at least 30 days; the first occurrence, in pa-
tients with a baseline eGFR of at least 30 ml per 
minute per 1.73 m2 and a baseline urinary albu-
min-to-creatinine ratio (with albumin measured 
in milligrams and creatinine measured in grams) 
of at least 300, of the above composite end point; 
the first occurrence of death from cardiovascular 
causes, hospitalization for heart failure, or an 
urgent visit for heart failure; deaths from cardio-
vascular causes; and deaths from any cause. The 
revised secondary end points were the total 
number of hospitalizations for heart failure and 
urgent visits for heart failure; deaths from car-
diovascular causes; the total number of deaths 
from cardiovascular causes, hospitalizations for 
heart failure, nonfatal myocardial infarctions, and 
nonfatal strokes; the total number of deaths from 
cardiovascular causes, hospitalizations for heart 
failure, urgent visits for heart failure, and events 
of heart failure during hospitalization; the first 
occurrence of the composite of a sustained de-
crease of at least 50% in the eGFR from baseline 
for at least 30 days, long-term dialysis, renal trans-
plantation, or a sustained eGFR of less than 15 ml 
per minute per 1.73 m2 for at least 30 days; deaths 
from any cause; and the total number of deaths 
from cardiovascular causes, nonfatal myocardial 
infarctions, and nonfatal strokes. The use of total 
events allowed for a single patient to have more 
than one event contributing to the analysis. Sub-
group analyses were prespecified. Because of loss 
of funding, planned adjudication of end-point 
events was not completed and investigator-report-
ed events were used for end-point analyses.
Statistical Analysis
The original design of the trial intended to estab-
lish the noninferiority of sotagliflozin to placebo 
with respect to the first occurrence of a MACE 
and the superiority of sotagliflozin over placebo 
with respect to the first occurrence of death from 
cardiovascular causes or hospitalization for heart 
failure. We estimated that for 10,500 randomly 
assigned patients, 1189 events would be needed 
to test for noninferiority with respect to the first 
occurrence of a MACE, on the basis of the upper 
boundary of a two-sided 95% confidence inter-
val for the hazard ratio being less than 1.3, and 
844 events would be needed to test for superior-
ity with respect to the first occurrence of death 
from cardiovascular causes or hospitalization for 
heart failure. In a hierarchical fashion, the copri-
mary end points and prespecified secondary end 
points were to be tested with a prespecified pro-
cedure to control for type I error. No formal power 
calculation was performed for the revised primary 
end point.
All efficacy analyses followed the intention-
to-treat principle. To allow for analyses of total 
events, competing-risk marginal models for re-
current events that were stratified according to 
heart-failure criteria and geographic region, with 
deaths not included in a given end point treated 
as competing terminal events, were applied to 
generate hazard ratios with Wald 95% confidence 
intervals and P values.31 Proportionality was con-
firmed by interaction terms between trial-group 
assignment and the logarithm of time. Event rates 
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Median age (IQR) — yr 69 (63–74) 69 (63–74)
Female sex — no. (%) 2347 (44.3) 2407 (45.5)
Race or ethnic group — no. (%)†
White 4402 (83.2) 4347 (82.1)
Black 176 (3.3) 188 (3.6)
Asian 317 (6.0) 365 (6.9)
American Indian or Alaska Native 206 (3.9) 216 (4.1)
Native Hawaiian or other Pacific Islander 25 (0.5) 15 (0.3)
Multiple 109 (2.1) 95 (1.8)
Unknown 57 (1.1) 66 (1.2)
Median glycated hemoglobin (IQR) — % 8.3 (7.6–9.3) 8.3 (7.6–9.4)
Median body-mass index (IQR) 31.9 (28.1–36.2) 31.7 (28.0–36.1)
Estimated glomerular filtration rate
Median (IQR) — ml/min/1.73 m2 44.4 (37.0–51.3) 44.7 (37.0–51.5)
Distribution — no. (%)
<30 ml/min/1.73 m2 419 (7.9) 394 (7.4)
30 to <45 ml/min/1.73 m2 2347 (44.3) 2308 (43.6)
≥45 ml/min/1.73 m2 2526 (47.7) 2590 (48.9)
Geographic region — no. (%)
Eastern Europe 1613 (30.5) 1613 (30.5)
Western Europe 711 (13.4) 709 (13.4)
Latin America 1586 (30.0) 1586 (30.0)
North America 746 (14.1) 747 (14.1)
Rest of the world 636 (12.0) 637 (12.0)
Ejection fraction of ≤40% within past year or hospitalization for 
heart failure during previous 2 years — no. (%)
1054 (19.9) 1054 (19.9)
History of heart failure — no. (%)‡ 1640 (31.0) 1643 (31.0)
Ejection fraction of <40% 505 (9.5) 528 (10.0)
Ejection fraction of 40 to <50% 290 (5.5) 291 (5.5)
Ejection fraction of ≥50% 843 (15.9) 824 (15.6)
Ejection fraction unknown 2 (<0.1) 0
Cardiovascular risk factors — no. (%)
At least one major 4682 (88.5) 4699 (88.8)
No major, at least two minor 405 (7.7) 413 (7.8)
No major and less than two minor 205 (3.9) 180 (3.4)
Previous myocardial infarction — no. (%) 1051 (19.9) 1057 (20.0)
Previous coronary revascularization — no. (%) 1208 (22.8) 1167 (22.1)
Previous stroke — no. (%) 472 (8.9) 474 (9.0)
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were summarized by the number of events per 
100 patient-years of follow-up,32 and accrual of 
events over time was summarized by cumulative 
incidence functions. For subgroup analyses, 95% 
confidence intervals are reported without adjust-
ment for multiple comparisons, and no conclu-
sions can be drawn from these data.
Total events of myocardial infarction and to-
tal events of stroke were evaluated post hoc. 
Testing for differences between the two groups in 
adverse events was performed post hoc; P values 
were obtained from Pearson chi-square tests. 
Change in the eGFR, glycated hemoglobin level, 
systolic blood pressure, diastolic blood pressure, 
and weight over time was analyzed post hoc by 
means of repeated-measures mixed-effects mod-
els with absolute change from baseline as the 
outcome, a random effect for intercept, and fixed 
effects for trial-group assignment, baseline val-
ue, and time. Changes in these outcomes were 
also jointly modeled with death from any cause 







Median (IQR) 74 (18–486) 75 (17–477)
Distribution — no. (%)
<30 1864 (35.2) 1845 (34.9)
30 to <300 1770 (33.4) 1819 (34.4)
≥300 1658 (31.3) 1628 (30.8)
Median left ventricular ejection fraction (IQR) — %‡ 60 (51–64) 60 (51–65)
Median NT-proBNP (IQR) — pg/ml 196.0 (75.1–564.6) 198.1 (74.6–560.7)
Median systolic blood pressure (IQR) — mm Hg 138 (127–149) 139 (127–149)
Median diastolic blood pressure (IQR) — mm Hg 78 (70–85) 78 (70–85)
Any RAAS inhibitor — no. (%)¶ 4705 (88.9) 4660 (88.1)
ACE inhibitor 2009 (38.0) 2039 (38.5)
Angiotensin-receptor blocker 2619 (49.5) 2562 (48.4)
Angiotensin receptor–neprilysin inhibitor 66 (1.2) 65 (1.2)
Mineralocorticoid-receptor antagonist 810 (15.3) 776 (14.7)
Beta-blocker — no. (%) 3310 (62.5) 3306 (62.5)
Calcium-channel blocker — no. (%) 2228 (42.1) 2202 (41.6)
Loop diuretic — no. (%) 1869 (35.3) 1867 (35.3)
Other diuretic — no. (%) 1568 (29.6) 1605 (30.3)
Any glucose-lowering medication — no. (%) 5111 (96.6) 5136 (97.1)
Metformin 2907 (54.9) 2955 (55.8)
Sulfonylurea 1400 (26.5) 1486 (28.1)
DPP-4 inhibitor 1041 (19.7) 1044 (19.7)
Insulin 3389 (64.0) 3333 (63.0)
GLP-1 receptor agonist 310 (5.9) 323 (6.1)
*  Percentages may not total 100 because of rounding. ACE denotes angiotensin-converting enzyme, DPP-4 dipeptidyl 
peptidase 4, GLP-1 glucagon-like peptide 1, IQR interquartile range, and NT-proBNP N-terminal pro–brain natriuretic 
peptide.
†  Race and ethnic group were reported by the investigators.
‡  Ejection fraction was measured within 1 year before screening or during the screening period.
§  The ratio was calculated with albumin measured in milligrams and creatinine measured in grams.
¶  Some patients were taking more than one renin–angiotensin–aldosterone system (RAAS) inhibitor.
Table 1. (Continued.)
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who discontinued the trial were censored for time-
to-event end points, and sensitivity analyses were 
performed, including imputation of the occur-
rence of events on the date that the patient was 
last known to be alive and imputation of the 
same for the sotagliflozin group only. Addi-
tional information on missing data is provided 
in the Supplementary Appendix.
R esult s
Patient Characteristics
A total of 19,188 patients were screened, of 
whom 10,584 were enrolled; 5292 were assigned 
to each trial group. Details regarding screening, 
randomization, and follow-up of the patients are 
shown in Figure S2. The median age of the pa-
tients was 69 years; 44.9% were female, and 
82.7% were White. Vital status was available for 
99.4% of the patients; 142 (1.3%) did not com-
plete final trial visits, of whom 67 had unknown 
end-of-trial vital status. The median duration of 
exposure to sotagliflozin was 14.2 months (in-
terquartile range, 10.3 to 18.9), and the median 
duration of exposure to placebo was 14.3 months 
(interquartile range, 10.3 to 18.9). The median 
duration of follow-up was 16.0 months (inter-
quartile range, 12.0 to 20.3) in the sotagliflozin 
group and 15.9 months (interquartile range, 11.9 
to 20.3) in the placebo group. In the sotagliflozin 
group, 3944 patients (74.5%) had an increase of 
the dose from 200 to 400 mg; in the placebo 
group, 4002 (75.6%) had the dose ostensibly in-
creased. Early discontinuation of the trial regi-
men for reasons other than death or early trial 
termination occurred in 578 patients (10.9%) in 
the sotagliflozin group and 597 patients (11.3%) 
in the placebo group.
Baseline characteristics were similar in the 
two groups (Table 1). Of all randomly assigned 
patients, 19.9% had an ejection fraction of 40% 
or less within the past year or hospitalization for 
heart failure during the previous 2 years, and the 
median left ventricular ejection fraction was 60% 
(interquartile range 51 to 65). The median gly-
cated hemoglobin level was 8.3%, median body-
mass index (the weight in kilograms divided by 
the square of the height in meters) was 31.8, 
median eGFR was 44.5 ml per minute per 1.73 m2 
(interquartile range, 37.0 to 51.4), and median 







(95% CI)† P Value
no. of events/100 patient-yr 
(no. of events)
Primary end point: total no. of deaths from cardiovascular causes, 
hospitalizations for HF, and urgent visits for HF
5.6 (400) 7.5 (530) 0.74 (0.63–0.88) <0.001
Major secondary end points, in order of hierarchical testing
Total no. or hospitalizations for HF and urgent visits for HF 3.5 (245) 5.1 (360) 0.67 (0.55–0.82) <0.001
Deaths from cardiovascular causes 2.2 (155) 2.4 (170) 0.90 (0.73–1.12) 0.35‡
Total no. of deaths from cardiovascular causes, hospitalizations 
for HF, nonfatal myocardial infarctions, and nonfatal strokes
7.6 (541) 10.4 (738) 0.72 (0.63–0.83) —
Total no. of deaths from cardiovascular causes, hospitalizations 
for HF, urgent visits for HF, and events of HF during hospi-
talization
6.4 (453) 8.3 (589) 0.76 (0.65–0.89) —
First occurrence of a sustained decrease of ≥50% in the eGFR 
from baseline for ≥30 days, long-term dialysis, renal transplan-
tation, or sustained eGFR of <15 ml/min/1.73 m2 for ≥30 days
0.5 (37) 0.7 (52) 0.71 (0.46–1.08) —
Deaths from any cause 3.5 (246) 3.5 (246) 0.99 (0.83–1.18) —
Total no. of deaths from cardiovascular causes, nonfatal myocar-
dial infarctions, and nonfatal strokes
4.8 (343) 6.3 (442) 0.77 (0.65–0.91) —
*  The term eGFR denotes estimated glomerular filtration rate, and HF heart failure.
†  Results are presented as point estimates and 95% confidence intervals unadjusted for multiple comparisons, from which no definite conclu-
sions regarding significant differences can be made.
‡  The hierarchical analysis stops after the first P value indicating nonsignificance.
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urinary albumin-to-creatinine ratio was 74 (in-
terquartile range, 17 to 481). Changes in the eGFR, 
glycated hemoglobin level, blood pressure, and 
weight are provided in Table S1.
End Points
There were 701 first and 930 total primary end-
point events. The distribution of primary end-
point events and competing deaths not from 
cardiovascular causes is shown in Table S2. The 
rates of total primary end-point events were 5.6 
and 7.5 events per 100 patient-years in the so-
tagliflozin and placebo groups, respectively (haz-
ard ratio, 0.74; 95% confidence interval [CI], 0.63 
to 0.88; P<0.001) (Table 2). The estimated time-
to-event curves for total primary end-point events 
are shown in Figure 1. Primary end-point events 
according to stratification factors and in selected 
prespecified subgroups are shown in Figure S3; 
however, the lack of a plan for adjustment of 
confidence intervals for multiple comparisons 
precludes conclusions from these data. Figure S4 
shows the results for the same end point minus 
urgent visits for heart failure. Table S3 shows 
results for prespecified subgroups and post hoc 
subgroups according to baseline history of heart 
failure and ejection fraction and according to 
geographic region and country; again, no defi-
nite conclusions can be drawn from these data.
For the total number of hospitalizations for 
heart failure and urgent visits for heart failure 
(first secondary end point), the rate was 3.5 events 
per 100-patient years in the sotagliflozin group 
and 5.1 events per 100-patient years in the place-
bo group (hazard ratio, 0.67; 95% CI, 0.55 to 0.82; 
P<0.001) (Table 2). There was no significant dif-
ference between the sotagliflozin and placebo 
groups in deaths from cardiovascular causes 
(second secondary end point) (2.2 and 2.4 per 
100 patient-years, respectively; hazard ratio, 0.90; 
95% CI, 0.73 to 1.12), and the hierarchical analy-
sis stopped at this point. However, results for the 
composite renal end point did not differ signifi-
cantly between the two groups, nor did all-cause 
mortality. Table S4 lists the original analysis 
plan for hierarchical testing of primary and sec-
ondary end points. The original coprimary end 
point of the first event of death from cardiovas-
cular causes or hospitalization for heart failure 
showed a hazard ratio of 0.77 (95% CI, 0.66 to 
0.91) (Fig. S5). The other original coprimary end 
point of the first event of death from cardiovas-
cular causes, nonfatal myocardial infarction, or 
nonfatal stroke showed a hazard ratio of 0.84 (95% 
CI, 0.72 to 0.99) (Fig. 2). Results for additional 
post hoc secondary end points are shown in 
Table S5. Prespecified and post hoc evaluations of 
composite end points as a function of normo-, 
micro-, and macroalbuminuria are presented in 
Tables S6 and S7, with no adjustment of confi-
dence intervals for multiple comparisons. For 
investigator-reported events submitted for adju-
dication before loss of trial funding, 337 of 501 
events (67.3%) in the sotagliflozin group and 
460 of 664 events (69.3%) in the placebo group 
were confirmed on adjudication (Table S8).
Adverse Events
There were no significant differences between 
the two groups in the percentage of patients with 
adverse events that occurred or worsened during 
the treatment period or with events leading to 
withdrawal of the trial regimen. The percentage 
of patients with a serious adverse event was 23.4% 
Figure 1. Total Number of Deaths from Cardiovascular Causes,  
Hospitalizations for Heart Failure, and Urgent Visits for Heart Failure.
Shown is a time-to-event analysis of the estimated number of events per 
100 patients for the primary end point of the total number of deaths from 
cardiovascular causes, hospitalizations for heart failure, and urgent visits 
for heart failure in the sotagliflozin and placebo groups. Total events after 
randomization are shown as estimated cumulative events per 100 patients 
instead of events per 100 patient-years to graphically show the time course 
of event accrual during follow-up. The number of competing deaths not 
from cardiovascular causes was 91 in the sotagliflozin group and 76 in the 
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in the sotagliflozin group and 25.2% in the pla-
cebo group (Table S9). Adverse events of special 
interest that were more common with sotagliflozin 
than with placebo were diarrhea (8.5% vs. 
6.0%; P<0.001), diabetic ketoacidosis (0.6% vs. 
0.3%; P = 0.02), genital mycotic infections (2.4% 
vs. 0.9%; P<0.001), and volume depletion (5.3% vs. 
4.0%; P = 0.003) (Table 3). There were no signifi-
cant between-group differences in bone fractures, 
urinary tract infections, severe hypoglycemia, 
acute kidney injury (2.2% in the sotagliflozin 
group and 2.1% in the placebo group; P=0.55), 
or amputations. The percentage of patients in 
whom hypertension developed was lower with 
sotagliflozin than with placebo (2.6% vs. 4.1%) 
(Table S10), whereas the percentage in whom hy-
potension developed was higher with sotagliflozin 
than with placebo (2.6% vs. 1.9%; P = 0.009).
Discussion
In our trial involving patients with type 2 diabetes 
mellitus, chronic kidney disease, and additional 
cardiovascular risks, the SGLT1/2 inhibitor sota-
gliflozin resulted in a lower risk of the compos-
ite primary end point of the total number of 
deaths from cardiovascular causes, hospitaliza-
tions for heart failure, and urgent visits for heart 
failure than placebo (5.6 vs. 7.5 events per 100 
patient-years). Deaths from cardiovascular causes 
and renal end points did not differ significantly 
between the trial groups. Diarrhea, genital my-
cotic infections, volume depletion, and diabetic 
ketoacidosis occurred with sotagliflozin.
Unlike some previous trials, our trial did not 
require that patients have a urinary albumin-to-
creatinine ratio of at least 200 or 300, and the 
trial examined cardiovascular events in a popu-
lation with a median albumin-to-creatinine ratio 
of 74. Our trial also did not require a history of 
heart failure or reduced ejection fraction at base-
line. Despite the low eGFR in our trial population 
(median, 44.5 ml per minute per 1.73 m2), kidney 
injury did not differ significantly between the 
sotagliflozin and placebo groups.
Potential mechanisms of action of SGLT2 in-
hibition include renal and systemic natriuretic 
effects, enhanced myocardial energetics, adaptive 
cellular reprogramming, increased red-cell mass 
affecting improved oxygen supply, weight loss, 
reductions in blood pressure and left ventricular 
hypertrophy, decreases in uric acid, and benefi-
cial effects on endothelial progenitor cells.33-41 
Sotagliflozin provides some degree of SGLT1 
inhibition as well, slowing intestinal glucose ab-
sorption and reducing postprandial glycemia. 
Mendelian randomization data have raised the 
possibility that SGLT1 inhibition might be as-
sociated with decreased rates of cardiovascular 
events.42 The SGLT1 blockade may have contrib-
uted to increased reports of diarrhea in our trial. 
Whether additional cardiovascular benefit is pro-
vided from SGLT1 inhibition above that provided 
by SGLT2 inhibition remains to be determined.
Limitations of this trial include premature 
cessation due to loss of funding that led to an 
inability to complete the intended duration of 
follow-up.30,43-46 Owing to concerns about the po-
tential for an inadequate number of events, the 
primary end point was changed to total number 
of events in an attempt to preserve statistical 
power. The change to a heart failure–related end 
point was made at a time when there was evidence 
that SGLT2 inhibitors as a class reduced heart fail-
ure, although sotagliflozin, with SGLT1/2 activity, 
had not been tested in this regard. The change 
Figure 2. First Occurrence of Death from Cardiovascular Causes, Nonfatal 
Myocardial Infarction, or Nonfatal Stroke.
Shown is a time-to-event analysis of the original primary end point of the 
estimated cumulative incidence for the first occurrence of death from car-
diovascular causes, nonfatal myocardial infarction, or nonfatal stroke in the 
sotagliflozin and placebo groups. The number of competing deaths not 
from cardiovascular causes was 80 in the sotagliflozin group and 69 in the 
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may have biased the findings toward benefit of 
the trial drug. The power to show a difference 
between the trial groups was not recalculated 
with the change of the end point; the trial re-
mained adequately powered for the original and 
revised primary end points but not for secondary 
end points, such as death from cardiovascular 
causes and progression of kidney disease. The 
trial design had called for adjudication of events, 
but this was not completed; therefore, investiga-
tor-defined end-point events were used for all 
analyses. Approximately 31% of adjudicated heart-
failure hospitalizations or urgent visits were not 
confirmed to be primary events (Table S8), lead-
ing to overestimation of the number of events.47-49 
Furthermore, hospitalization for reasons other 
than heart failure would remove patients from 
the risk of a primary end-point event, although 
fewer total hospitalizations in the sotagliflozin 
group than in the placebo group (1923 vs. 2094) 
spanning fewer total patient-years (104 vs. 119) 
suggest the absence of bias favoring sotagliflozin 
with respect to the primary end point.
The SGLT1/2 inhibitor sotagliflozin resulted 
in a lower risk of the composite of deaths from 
cardiovascular causes, hospitalizations for heart 
failure, and urgent visits for heart failure than 
placebo among patients with diabetes mellitus 
and chronic kidney disease, with or without albu-
minuria. The results in the sotagliflozin group 
did not differ significantly from those in the 
placebo group with respect to rates of death from 
cardiovascular causes or renal end points, and 
sotagliflozin was associated with serious adverse 
events. Longer trials are required to evaluate the 
effect and safety of sotagliflozin in patients with 
diabetes and chronic kidney disease.
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(N = 5286) P Value†
no. of patients (%)
Urinary tract infections 610 (11.5) 585 (11.1) 0.45
Diarrhea 448 (8.5) 315 (6.0) <0.001
Volume depletion 278 (5.3) 213 (4.0) 0.003
Bone fractures 111 (2.1) 117 (2.2) 0.68
Genital mycotic infections 125 (2.4) 45 (0.9) <0.001
Severe hypoglycemia 53 (1.0) 55 (1.0) 0.84
Malignant conditions 47 (0.9) 42 (0.8) 0.60
Venous thrombotic events 31 (0.6) 37 (0.7) 0.46
Adverse event leading to amputation 32 (0.6) 33 (0.6) 0.89
Diabetic ketoacidosis 30 (0.6) 14 (0.3) 0.02
Pancreatitis 12 (0.2) 20 (0.4) 0.16
*  Shown are adverse events that first occurred or worsened in severity on or af-
ter the date of the first dose of sotagliflozin or placebo and within 10 days (1 
day for hypoglycemia) after the last dose. Percentages are based on the safety 
population, which comprised all the patients who underwent randomization 
and who received at least one dose of sotagliflozin or placebo. Unlike Table 
S10, which shows adverse events according to single preferred terms, Table 
3 groups multiple preferred terms together under one composite term; there-
fore, values may differ slightly between the two tables. The preferred terms 
that are included in each composite term are shown in the final statistical 
analysis plan. All adverse events are coded according to the Medical Dictionary 
for Regulatory Activities, version 23.0.
†  P values were calculated with the Pearson chi-square test.
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